Aim: To determine the minimal effective dose of Foot and Mouth disease (FMD) serotypes (A, O, SAT2) according to antigenic content (146S) in order to produce a potent trivalent FMD vaccine.
Introduction
. There are seven antigenically distinct serotypes of FMDV (A, O, C, South African Territories (SAT) types Foot and mouth disease (FMD) is an economically 1-3 and Asia-1) and each serotype has many subtype devastating disease of livestock. Although vaccines, variants. This antigenic variation creates a major available since the early 1900s, have been instrumental problem for the control of FMD, as infection or in eradicating FMD from parts of the world, the disease vaccination with one serotype of FMDV does not still affects millions of animals around the globe and protect against other serotypes and may fail to protect remains the main sanitary barrier to the commerce of fully against other subtypes within the same serotype animals and animal products [1] [5]. Although mortality is usually low, morbidity can Foot and mouth disease harvest contain three reach 100% causing severe losses in production. virus specific particles: (i) the infective 146S virus Therefore, the disease remains a major economic particle, comprising one molecule of ss RNA and 60 concern for livestock-health in many developing countries copies of each of four polypeptides VP1,VP2,VP3 and and a continued threat to disease free countries [2, 3] VP4; ( ii) the empty 75S particles, devoid of RNA and The causative agent of FMD is a small positive comprising 60 copies of each of VP1,VP3 and VP0 sense ssRNA virus (approx. 8.3 kb) which belongs to (precursor of VP2 and VP4); (iii) the 12S particle the Aphthovirus genus of the family Picornaviridae consisting of VP1,VP2 and VP3 but devoid of VP4 [6] In Egypt, the disease is enzootic and outbreaks have been reported since 1950. FMD serotypes 'SAT2', 'A' and 'O' were reported in the years 2012, 1972 and 2000, respectively [7-10] . Virus type 'O' was which is evaluated as GPPD , determination of 50 incriminated in the last two epidemic outbreaks, which antibodies in G. Pigs and cattle, so as to be safe and occurred in 1987 and 1993. potent. In addition, determination of the optimal 146S Vaccination is the only approach to control FMD. content aids to avoid the challenge of vaccinated The immunogenicity of foot and mouth disease (FMD) animals during the vaccine evaluation test which may vaccines depends to a large extent on the production of result in infection of animals with the virulent viral whole virions (146S particles), in tissue culture and the strains. stability of these particles after virus inactivation
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procedures and formulation into vaccines. [11] .
Experimental guinea pigs: Healthy adult male albino The quantity of 146S particles in inactivated guinea pigs approximately of 400-500 gm body weight FMD virus vaccine samples produced in FMD Vaccine were used for preparation of guinea pig adapted FMD Production Center is generally estimated by the virus to be used for Guinea pig challenge and for sucrose gradient ultracentrifugation and optical determination of GPPD of the prepared vaccines. density analysis by using the computer applying 50 system [12] .
Ethical approval: The experiment was as per the The use of 146S assay only or some serological protocol of Institutional Animal Ethics Committee, the tests which together increase the reliance on estimating authors had taken permission of animal owners of potency of specific vaccine batch. They can also be private farm. assembled with an interconnected method which is based on the 146S concentration of the final vaccine carried out according to earlier reports [20, 21] . tests must be carried out in containments having high biosecurity levels. There are many publications Guinea pig adapted virus: Albino Guinea pigs were indicating a correlation between protections from virus inoculated by FMD virus strain O pan Asia-2, A Iran challenge and neutralizing antibody response.
O5 and SAT2 / EGY/2012 intradermoplanter in the However, up to now, none of the suggested method has metatarsal pads. After 24-48 hours the developed been found valid [13] .
lesions were collected aseptically. The lesions extract Guinea pigs were chosen as experimental models was again re-inoculated in other Guinea pigs 5 times to develop concepts and techniques to study the until the virus became quite adapted to Guinea pigs as protective dose 50 (PD ) of FMD vaccines because of 50 recommended earlier [22] . the similarities of clinical symptoms in these animals to Virus purification: Aseptically, the harvested culture those of swine and cattle to saving cost [15, 16] . Guinea medium from FMD virus infected BHK cell cultures pigs are susceptible animals to FMD and can be 21 protected by aqueous FMD vaccines. The methods of were centrifuged in a cooling centrifuge at 7000 rpm demonstrating the potency of such vaccines using for 20 minutes to remove cell debris [23] . Guinea pigs have been described having a good FMD vaccines depending on its antigenic content then the inactivation occur by using combination of (146S) and detection of vaccine potency which is BEI 1mM and 0.04% FA (BEI-FA) according to the expressed as 50% Guinea pig protective doses method described previously [24, 25] . 2% of each of (GPPD ) aiming to produce a potent trivalent vaccine 50 sodium thiosulphate (20%) and sodium bisulphite 4-5 days of the challenge test for the development of (20%) were added after inactivation process to primary and secondary lesions. If the virus generalizes neutralize the excess of BEI and formalin.
in the guinea pig's body, the vesicles on the uninoculated feet and the tongue are observed for a 146S particles in the virus preparation was estimated present work. This vaccine was inoculated as 0.5ml in by using sucrose density gradient ultracentrifugation each of 5groups of Guinea pigs and each group was by determining the absorbance at 254 nm using ISCO challenged with one of the FMD viral serotype (either 520 C Density Gradient system as described previously O pan Asia-2 or A Iran O5 or SAT2/EGY/2012) after 4 [26, 27] .
weeks. Serum samples were collected pre-vaccination and weekly for 4 weeks post vaccination. Serum Vaccine formulation was done according to the neutralization test was performed on the serum method described earlier [28, 29] as follows: The oil samples as described earlier [31] and the antibody titer phase consisted of Montanide ISA 206, mixed as equal was expressed as log . with CFT value of 64, 32 and 32; total protein of the for O Pan Asia-2, A Iran O5 and SAT/EGY/2012) FMDV 3.8, 3.7 and 3.5 mg/ml and 146S antigenic respectively, but using 2.8µg of 146S, induced GPPD 50 content 4, 3.5 and 3 µg/ml before the concentration was 161.7, 105.8 and 161.7 for O Pan Asia-2, A Iran O5 respectively but the 146S was reached to 5.7, 5.2 and and SAT/EGY/2012 respectively. These results are 4.8 µg/ml after concentration with PEG as tabulated in tabulated in Table-2 , 3, 4, and 5. These results were in Table- that after the vaccines were inoculated subcutaneously and 2.8µg/ml with all serotype while the SNT was 0.9, on the back foot in two groups of guinea pigs, just two 0.7 and 0.7 using 1.6 µg/ml of 146S for (O Pan Asia-2, of ten animals showed antiserum titration above the A Iran O5 and SAT/EGY/2012) respectively but it was protective titer (PT=1.2), and the other 8 animals were 1.6, 1.55, 1.7 using 2.2 µg/ml of 146S for (O Pan Asiabelow the PT. 2, A Iran O5 and SAT/EGY/2012) respectively also it Finally we used the Guinea pigs as model for was 1.84, 1.75, 1.86 using 2.8 µg/ml of 146S for (O Pan vaccine evaluation instead of cattle to lower the cost Asia-2, A Iran O5 and SAT/EGY/2012) respectively. during the vaccine evaluation, so to confirm these These findings are in agreement with previous report results we made field application to the experimental [36] that showed that the protective titer of SNT in prepared vaccine to confirm that the amount of 146S Guinea pigs is 1.2.
used is sufficient to protect cattle from FMDV, as The above mentioned results indicate that the shown in Table- reached its maximum antibody level at 10WPV (3.15) The new formulated prepared vaccine as 2.2 µg of and extended as a protective SN antibody titer from 2 to 146S payload from each virus type with equal volume 32 WPV while the antibody titer against serotype (A) from the oil was diluted (undiluted, ¼, 1/16, 1/64, started as 0.3 at 0 WPV and reached its maximum titer 1/256) and each dilution was inoculated in each of 5 at 8,10 and 12 WPV, the protective (1.5) extended from Guinea pigs. The obtained GPPD was found to be 88 2 to 34WPV. The SN antibody titer against FMDV 50 as shown in Table- 6. Such obtained GPPD50 appeared serotype (SAT) was zero at 0 WPV and reached its to be higher than the recommended one, the thing that maximum antibody titer (3.15) at 10 WPV, the confirms the high potency of the prepared vaccine.
protective antibody titer (1.5) extended from 2 to 32 Testing of Guinea pigs serum samples, to confirm WPV. From these results, the antibody titer against the the results of GPPD using SNT, showed antibody three serotypes were found to be higher than the 50 recommended titer (1.5) which extended for 32 WPV titers of 1.56, 1.68 and 1.68 log /ml against FMDV and antibody titer of the Guinea pigs of the prepared (1.5 log for SNT and 1.9 log for ELISA) for both of 10 10 th trivalent vaccine with 146S (2.2 µg/serotype/dose) type A and O as estimated by SNT and ELISA on the 4 these results come in agreement with previous reports week post vaccination to record peak titers by the 12 [28, 30, 33, 40] who mentioned that vaccination of week post vaccination for both types. These antibody calves with the locally produced bivalent FMD vaccine titers remained within the protective level up to 36 adjuvanted with Montanide ISA 206 induced higher weeks post vaccination in the 2 farms under study. antibody titers than the recommended protective level 
